Back to today’s briefing

Story perspectives

Eli Lilly's Inluriyo Approved: Promising Breast Cancer Breakthrough

9/26/2025

47 7 Full Breakdown

Summary

Story summary

Eli Lilly's Inluriyo gained FDA approval for ESR1 mutations in breast cancer.
Trial showed a 38% reduction in progression or death vs standard therapies.
Median progression-free survival was 5.5 months with Inluriyo versus 3.8 months.
Drug costs $22,500 for a 28-day supply and carries a fetal-harm warning.
Future studies will test its use in early-stage breast cancer, results in 2027.

1 of 1

Story summary

Eli Lilly's Inluriyo gained FDA approval for ESR1 mutations in breast cancer.
Trial showed a 38% reduction in progression or death vs standard therapies.
Median progression-free survival was 5.5 months with Inluriyo versus 3.8 months.
Drug costs $22,500 for a 28-day supply and carries a fetal-harm warning.
Future studies will test its use in early-stage breast cancer, results in 2027.